Evidence map›Paper›PMID 36979600›Full record

ReviewBiosensors2023

Biomarker Detection in Early Diagnosis of Cancer: Recent Achievements in Point-of-Care Devices Based on Paper Microfluidics.

Bilge Asci Erkocyigit, Ozge Ozufuklar, Aysenur Yardim, Emine Guler Celik, Suna Timur

Open access · goldFull text readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biosensors, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 2 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Multi-omics analysis linksTranslational cancer research · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Bilge Asci ErkocyigitDepartment of Biotechnology, Institute of Natural Sciences, Ege University, Izmir 35100, Turkey.
Ozge OzufuklarDepartment of Biotechnology, Institute of Natural Sciences, Ege University, Izmir 35100, Turkey.
Aysenur YardimDepartment of Bioengineering, Institute of Natural Sciences, Ege University, Izmir 35100, Turkey.ORCID 0000-0003-4762-7292
Emine Guler CelikDepartment of Bioengineering, Faculty of Engineering, Ege University, Izmir 35100, Turkey.
Suna TimurDepartment of Biochemistry, Faculty of Science, Ege University, Izmir 35100, Turkey.
Ege University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microfluidics is very crucial in lab-on-a-chip systems for carrying out operations in a large-scale laboratory environment on a single chip. Microfluidic systems are miniaturized devices in which the fluid behavior and control can be manipulated on a small platform, with surface forces on the platform being greater than volumetric forces depending on the test method used. In recent years, paper-based microfluidic analytical devices (μPADs) have been developed to be used in point-of-care (POC) technologies. μPADs have numerous advantages, including ease of use, low cost, capillary action liquid transfer without the need for power, the ability to store reagents in active form in the fiber network, and the capability to perform multiple tests using various measurement techniques. These benefits are critical in the advancement of paper-based microfluidics in the fields of disease diagnosis, drug application, and environment and food safety. Cancer is one of the most critical diseases for early detection all around the world. Detecting cancer-specific biomarkers provides significant data for both early diagnosis and controlling the disease progression. μPADs for cancer biomarker detection hold great promise for improving cure rates, quality of life, and minimizing treatment costs. Although various types of bioanalytical platforms are available for the detection of cancer biomarkers, there are limited studies and critical reviews on paper-based microfluidic platforms in the literature. Hence, this article aims to draw attention to these gaps in the literature as well as the features that future platforms should have.

Indexed as

Microfluidic Analytical TechniquesNeoplasmsBiomarkers, TumorEarly Detection of CancerHumansLab-On-A-Chip DevicesMicrofluidicsPaperPoint-of-Care SystemsQuality of LifeBiomarkers, Tumorbiomarker detectioncancer biomarkersin vitro diagnosticspaper-based microfluidicspoint-of-care testing (POCT)

Identifiers

PMID36979600
PMCPMC10046104
OpenAlexW4327624186

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.